Business
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has ...
About this update from Clearpoint Neuro Inc.
[{"type":"text","content":"SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2.","length":343,"tagName":"p"},{"type":"text","content":""By achieving CE Mark for the ClearPoint Navigation 3.0.2 software, we are able to unify our global navigation platform which we believe will enable consistent training and hospital IT support," commented Mazin Sabra, Chief Operating Officer at ClearPoint Neuro. "We expect that this will also help us to not only satisfy our biopharma partners who want a global solution, but also reduce our operating costs and drive economies of scale."","length":459,"tagName":"p"},{"type":"text","content":"ClearPoint Navigation Software Version 3.x was first introduced in the United States following FDA clearance 11 months ago and has already been adopted by most US customers. "By releasing our latest version of software to our EU customers, we are excited to offer feature refinements developed through years of valuable user experience and feedback," stated Tim Orr, VP of Software Development at ClearPoint Neuro. "The 3.0.2 release represents an important milestone which will allow us to unify US and EU customers on the same navigation platform."","length":570,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"ClearPoint Neuro, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":777,"height":417,"url":"https://media.zenfs.com/en/accesswire.ca/7a759a101afb1968639181adb62eb294"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BYcM0Oe3OQX9StjWb_4tAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxNTtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/7a759a101afb1968639181adb62eb294","width":777,"height":417},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Y8.I.5et8dluLFbw4Q5xGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1NTQ7aD04MzQ7Y2Y9d2VicA--/https://media.zenfs.com/en/accesswire.ca/7a759a101afb1968639181adb62eb294","width":777,"height":417}},"href":"https://app.accessnewswire.com/imagelibrary/1dd05280-cc64-49f2-9f63-c346cda7e5b5/image.png","hrefExternal":true,...